Brentuximab Vedotin After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies
Condition(s):Hematopoietic/Lymphoid CancerLast Updated:April 21, 2014Withdrawn
Hide Studies Not Open or Pending
Condition(s):Hematopoietic/Lymphoid CancerLast Updated:April 21, 2014Withdrawn
Condition(s):Disease, HodgkinLast Updated:December 18, 2014Completed
Condition(s):Mycosis Fungoides; Sézary SyndromeLast Updated:August 30, 2019Completed
Condition(s):Hodgkin Disease; Lymphoma, T-Cell, Peripheral; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Large-Cell, AnaplasticLast Updated:February 12, 2024Not yet recruiting
Condition(s):Peripheral T-cell LymphomaLast Updated:February 20, 2024Active, not recruiting
Condition(s):Lymphoma, T-Cell, Cutaneous; Hodgkin Disease; Lymphoma, T-Cell, Peripheral; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-HodgkinLast Updated:March 5, 2024Recruiting
Condition(s):Classic Hodgkin Lymphoma; Recurrent Hodgkin Lymphoma; Refractory Hodgkin LymphomaLast Updated:October 30, 2023Active, not recruiting
Condition(s):Hodgkin Disease; Peripheral T Cell LymphomaLast Updated:September 28, 2023Completed
Condition(s):Hodgkin Lymphoma; Refractory; RelapseLast Updated:March 13, 2018Unknown status
Condition(s):Carcinomas; Disease, Hodgkin; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; NeoplasmsLast Updated:December 18, 2014Completed
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.